An Innovative Approach to Immunotherapy [Developing the Immune System]
Therapeutic agents for markets with high under media needs: infectious diseases.
Initial discovery: Synthetic peptides.
The need: Viral infections and cancers dysregulate the immune system, which allows progression of the disease. A new approach to therapy is needed to modulate the immune system.
Approach: Design peptide drugs that bind lectin-type receptor to activate cellular processes at very low concentrations.
Triggering cellular processes and then metabolized. This means high avidity and low toxicity.
Focus: Cells must be activated to destroy aberrant cells. Modulation of immune system is achieved by identification of peptides that bind to specific areas of a cell.
Phage sequence: PIII Protein. DNA synthesis: Amino acids that act as sugars in the system. Peptide sequences that mimic sugars were also identified by computer modeling of interaction with lectin as receptor analogs.
In order to complete the reaction binding energy is needed= –ΔG.
(Negative values for energy input).
Lectin type receptors are important in the process of detecting specific sialic acid-containing.
Function: Sialic acid-rich glycoproteins (sialoglycoproteins) bind selectin in humans and other organisms. Metastatic cancer cells often express a high density of sialic acid-rich glycoproteins. This over expression of sialic acid on surfaces creates a negative charge on cell membranes. This creates repulsion between cells (cell opposition) and helps these late-stage cancer cells enter the blood stream.
Solid-phase binding assay for peptide-lectin interaction.
Blue color predicts the amount of peptide you created. The peptide binds as a monomer, and the phosphorylation.
Results: Intracellular fluorescence color in tests predicts the formation.
Benefits: Reduce HIV-related morbidity and prolong survival. Improve quality of life. Maximally and durably suppress viral load. Prevent HIV transmission. HIV inhibition, and inhibits replication.
Restore and Preserve Immunological System.
Test: In-vitro assays proved that svH1C eliminated HIV culture of peripheral blood mononuclear cells present in the blood-antibodies.
Glioblastoma: Survival of mice when tumor was exposed to brief radiation. The more phosphorylated, the more active the receptor to activate the cell. Dephosphorylated removes its activity to serve as a receptor. Inhibitory receptors or decrease this allows the activated signals to be expressed even more.
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain cancer
Glioma cells: Cells with same histological features.
A glioma is a type of tumor that starts in the brain or spine. It is called a glioma because it arises from glial cells. The most common site of gliomas is the brain. Gliomas make up ~30% of all brain and central nervous system tumors and 80% of all malignant brain tumors.
Brain microglial cells, and dendritic cells. Promotes maturation of dendritic cells in the brain.
Overall
Susavion compounds should be effective in immunotherapeutic treatment of diseases in which the immune system is suppressed helping the body to defend itself.
Further research: Delivery system: epithelium absorption and how to get absorption into the digestive system.
Reference: https://www.sciencemag.org/news/2015/10/designer-antibodies-may-rid-body-aids-virus
Esther Juárez 